JP2022512589A5 - - Google Patents

Info

Publication number
JP2022512589A5
JP2022512589A5 JP2021518190A JP2021518190A JP2022512589A5 JP 2022512589 A5 JP2022512589 A5 JP 2022512589A5 JP 2021518190 A JP2021518190 A JP 2021518190A JP 2021518190 A JP2021518190 A JP 2021518190A JP 2022512589 A5 JP2022512589 A5 JP 2022512589A5
Authority
JP
Japan
Prior art keywords
aav
seq
pharmaceutical composition
acid sequence
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021518190A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022512589A (ja
JP7534290B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/053797 external-priority patent/WO2020072354A1/en
Publication of JP2022512589A publication Critical patent/JP2022512589A/ja
Publication of JP2022512589A5 publication Critical patent/JP2022512589A5/ja
Priority to JP2024125570A priority Critical patent/JP2024161415A/ja
Application granted granted Critical
Publication of JP7534290B2 publication Critical patent/JP7534290B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021518190A 2018-10-01 2019-09-30 Gm1ガングリオシドーシスの治療に有用な組成物 Active JP7534290B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024125570A JP2024161415A (ja) 2018-10-01 2024-08-01 Gm1ガングリオシドーシスの治療に有用な組成物

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862739811P 2018-10-01 2018-10-01
US62/739,811 2018-10-01
US201962835178P 2019-04-17 2019-04-17
US62/835,178 2019-04-17
PCT/US2019/053797 WO2020072354A1 (en) 2018-10-01 2019-09-30 Compositions useful for treating gm1 gangliosidosis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024125570A Division JP2024161415A (ja) 2018-10-01 2024-08-01 Gm1ガングリオシドーシスの治療に有用な組成物

Publications (3)

Publication Number Publication Date
JP2022512589A JP2022512589A (ja) 2022-02-07
JP2022512589A5 true JP2022512589A5 (cg-RX-API-DMAC7.html) 2022-10-06
JP7534290B2 JP7534290B2 (ja) 2024-08-14

Family

ID=69165478

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021518190A Active JP7534290B2 (ja) 2018-10-01 2019-09-30 Gm1ガングリオシドーシスの治療に有用な組成物
JP2024125570A Pending JP2024161415A (ja) 2018-10-01 2024-08-01 Gm1ガングリオシドーシスの治療に有用な組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024125570A Pending JP2024161415A (ja) 2018-10-01 2024-08-01 Gm1ガングリオシドーシスの治療に有用な組成物

Country Status (16)

Country Link
US (1) US12594327B2 (cg-RX-API-DMAC7.html)
EP (1) EP3860659A1 (cg-RX-API-DMAC7.html)
JP (2) JP7534290B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210071017A (cg-RX-API-DMAC7.html)
CN (1) CN113438954A (cg-RX-API-DMAC7.html)
AU (1) AU2019351815B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021006060A2 (cg-RX-API-DMAC7.html)
CA (1) CA3114175A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021000798A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021005443A2 (cg-RX-API-DMAC7.html)
IL (1) IL281923A (cg-RX-API-DMAC7.html)
MX (1) MX2021003869A (cg-RX-API-DMAC7.html)
PE (1) PE20211596A1 (cg-RX-API-DMAC7.html)
SA (1) SA521421639B1 (cg-RX-API-DMAC7.html)
SG (1) SG11202102942VA (cg-RX-API-DMAC7.html)
WO (1) WO2020072354A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3860659A1 (en) 2018-10-01 2021-08-11 The Trustees of the University of Pennsylvania Compositions useful for treating gm1 gangliosidosis
WO2021155337A1 (en) * 2020-02-02 2021-08-05 The Trustees Of The University Of Pennsylvania Compositions useful for treating gm1 gangliosidosis
TWI910162B (zh) * 2020-05-05 2026-01-01 美國公爵大學 跨物種相容腺相關病毒組合物及其使用方法
CN116926047A (zh) * 2022-03-31 2023-10-24 北京锦篮基因科技有限公司 功能性β-半乳糖苷酶变体、AAV介导的人β-半乳糖苷酶表达载体及其用途
WO2024040258A2 (en) * 2022-08-19 2024-02-22 Codexis, Inc. Engineered beta- galactosidase polypeptides
JP2025533863A (ja) * 2022-10-12 2025-10-09 ノベルファーマ株式会社 Gm1ガングリオシド症又はモルキオ症候群b型の治療、予防又は改善用薬学的組成物及びその投与方法

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US5436146A (en) 1989-09-07 1995-07-25 The Trustees Of Princeton University Helper-free stocks of recombinant adeno-associated virus vectors
US6268213B1 (en) 1992-06-03 2001-07-31 Richard Jude Samulski Adeno-associated virus vector and cis-acting regulatory and promoter elements capable of expressing at least one gene and method of using same for gene therapy
US5869305A (en) 1992-12-04 1999-02-09 The University Of Pittsburgh Recombinant viral vector system
US6204059B1 (en) 1994-06-30 2001-03-20 University Of Pittsburgh AAV capsid vehicles for molecular transfer
US5741683A (en) 1995-06-07 1998-04-21 The Research Foundation Of State University Of New York In vitro packaging of adeno-associated virus DNA
US6093570A (en) 1995-06-07 2000-07-25 The University Of North Carolina At Chapel Hill Helper virus-free AAV production
EP1007637B1 (en) 1997-04-14 2004-06-30 Cell Genesys, Inc. Methods for increasing the efficiency of recombinant aav product
US6146874A (en) 1998-05-27 2000-11-14 University Of Florida Method of preparing recombinant adeno-associated virus compositions
EP1135468B1 (en) 1998-11-10 2010-01-06 University Of North Carolina At Chapel Hill Virus vectors and methods of making and administering the same
AU6814901A (en) 2000-06-01 2001-12-11 Univ North Carolina Methods and compounds for controlled release of recombinant parvovirus vectors
CN103589692B (zh) 2001-11-13 2018-07-24 宾夕法尼亚大学托管会 检测和/或鉴定腺伴随病毒(aav)序列以及分离所鉴定的新型序列的方法
AU2003274397A1 (en) 2002-06-05 2003-12-22 University Of Florida Production of pseudotyped recombinant aav virions
US8005620B2 (en) 2003-08-01 2011-08-23 Dna Twopointo Inc. Systems and methods for biopolymer engineering
WO2005012877A2 (en) 2003-08-01 2005-02-10 Dna Twopointo Inc. Systems and methods for antibody engineering
EP1668143B1 (en) 2003-09-30 2013-03-20 The Trustees of The University of Pennsylvania Adeno-associated virus (aav) clades, sequences, vectors containing same, and uses therefor
DE23193606T1 (de) 2005-04-07 2024-02-15 The Trustees Of The University Of Pennsylvania Verfahren zur erhöhung der funktion eines aav-vektors
US7588772B2 (en) 2006-03-30 2009-09-15 Board Of Trustees Of The Leland Stamford Junior University AAV capsid library and AAV capsid proteins
PL2158322T3 (pl) * 2007-06-06 2017-10-31 Genzyme Corp Terapia genowa dla lizosomalnych chorób spichrzeniowych
US8734809B2 (en) 2009-05-28 2014-05-27 University Of Massachusetts AAV's and uses thereof
WO2011126808A2 (en) 2010-03-29 2011-10-13 The Trustees Of The University Of Pennsylvania Pharmacologically induced transgene ablation system
US9315825B2 (en) 2010-03-29 2016-04-19 The Trustees Of The University Of Pennsylvania Pharmacologically induced transgene ablation system
US8927514B2 (en) 2010-04-30 2015-01-06 City Of Hope Recombinant adeno-associated vectors for targeted treatment
FR2977562B1 (fr) 2011-07-06 2016-12-23 Gaztransport Et Technigaz Cuve etanche et thermiquement isolante integree dans une structure porteuse
WO2013151664A1 (en) * 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins
US9719106B2 (en) 2013-04-29 2017-08-01 The Trustees Of The University Of Pennsylvania Tissue preferential codon modified expression cassettes, vectors containing same, and uses thereof
JP2016523835A (ja) 2013-05-15 2016-08-12 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ 中枢神経系へのアデノ随伴ウイルスを介した遺伝子導入
WO2016049230A1 (en) 2014-09-24 2016-03-31 City Of Hope Adeno-associated virus vector variants for high efficiency genome editing and methods thereof
EP3285788B1 (en) * 2015-04-23 2024-12-18 University of Massachusetts Modulation of aav vector transgene expression
AU2016343979A1 (en) 2015-10-29 2018-05-10 Voyager Therapeutics, Inc. Delivery of central nervous system targeting polynucleotides
US20190060359A1 (en) 2015-11-02 2019-02-28 Neuraltus Pharmaceuticals, Inc. Treatment of neurodegenerative disease with sodium chlorite
EP3387138B2 (en) 2015-12-11 2026-05-27 The Trustees Of The University Of Pennsylvania Scalable purification method for aav9
MA43968A (fr) 2016-02-03 2018-12-12 Univ Pennsylvania Thérapie génique pour traiter la mucopolysaccharidose de type i
HRP20231451T1 (hr) 2016-02-05 2024-03-01 Emory University Ubrizgavanje jednolančanog ili samo-komplementarnog adeno-povezanog virusa 9 u cerebrospinalnu tekućinu
WO2018045347A1 (en) 2016-09-02 2018-03-08 Spark Therapeutics, Inc. Methods and vectors for treating cns disorders
IL309808B2 (en) 2016-11-15 2025-04-01 Univ Minnesota Method for improving neurological function in MPSI and MPSII and other neurological disorders
RS65241B1 (sr) 2017-02-28 2024-03-29 Univ Pennsylvania Vektor adeno-asociranih virusa (aav) iz podgrupe f i njegove upotrebe
WO2019222314A1 (en) 2018-05-15 2019-11-21 University Of Massachusetts Raav vectors encoding of lysosomal beta-galactorsidase (glb1) and cathepsin a
EP3860659A1 (en) 2018-10-01 2021-08-11 The Trustees of the University of Pennsylvania Compositions useful for treating gm1 gangliosidosis
CA3115251A1 (en) 2018-10-05 2020-04-09 University Of Massachusetts Raav vectors for the treatment of gm1 and gm2 gangliosidosis
BR112021009913A2 (pt) 2018-12-05 2021-08-17 Abeona Therapeutics, Inc. vetor viral adeno-associado recombinante para inserção gênica
WO2021155337A1 (en) 2020-02-02 2021-08-05 The Trustees Of The University Of Pennsylvania Compositions useful for treating gm1 gangliosidosis

Similar Documents

Publication Publication Date Title
JP7860176B2 (ja) 変異aav、及び、細胞、臓器並びに組織への遺伝子導入のための組成物、方法並びに使用法
US12281321B2 (en) Frataxin expression constructs having engineered promoters and methods of use thereof
JP2026027271A5 (cg-RX-API-DMAC7.html)
JP6805174B2 (ja) 神経成長因子シグナルペプチド及び副甲状腺ホルモンを含むaav分離株及び融合タンパク質
JP2023504773A5 (cg-RX-API-DMAC7.html)
JP2022531861A5 (cg-RX-API-DMAC7.html)
US20150111955A1 (en) Aav vector compositions and methods for gene transfer to cells, organs and tissues
WO2022164351A1 (en) Synergistic effect of smn1 and mir-23a in treating spinal muscular atrophy
JP2021533126A (ja) 臓器機能を制御するための遺伝子治療方法
CN113121651A (zh) 新型低中和抗体腺相关病毒衣壳蛋白
CN118108810A (zh) 一种靶向骨骼肌的重组腺相关病毒及其应用
CN114276419B (zh) 肌肉高亲和性的新型腺相关病毒衣壳蛋白及其应用
WO2023165477A1 (zh) 白介素1受体拮抗蛋白的表达盒以及基于aav的基因递送系统
JP2023513487A5 (cg-RX-API-DMAC7.html)
JP5728389B2 (ja) アラニン−グリオキシル酸アミノトランスフェラーゼ治療薬
JP2024528997A (ja) 放射線誘発性唾液機能低下を予防するためのaqp1遺伝子療法
US20240076691A1 (en) Codon-optimized nucleic acid encoding the fix protein
JP2025014677A (ja) 血管平滑筋細胞指向カプシド、アデノ随伴ウイルスベクター、医薬組成物、治療方法、核酸導入方法、及びカプシド製造方法
WO2025060451A1 (zh) 经修饰的腺相关病毒载体及其在治疗神经疾病中的用途
CN116590342A (zh) 一种aav载体及其应用
HK40109258A (en) Codon-optimized nucleic acid encoding the fix protein
RU2837753C2 (ru) Вариант aav, композиции и способы, в которых он используется, а также способы его применения для переноса генов в клетки, органы и ткани
WO2025065890A1 (zh) 一种重组腺相关病毒颗粒、重组腺相关病毒载体系统及其应用
JP2023526311A5 (cg-RX-API-DMAC7.html)
CN119730884A (zh) 与重组病毒载体相关的不良反应的预防或减轻